XASX
VHL
Market cap46mUSD
May 19, Last price
0.04AUD
Name
Respiri Ltd
Chart & performance
P/E
—
P/S
144.80
EPS
—
Div yield, %
—
Shrs. gr., 5y
15.31%
Rev. gr., 5y
-14.94%
Revenues
457k
+547.80%
Net income
-7m
L+23.44%
CFO
-7m
L+47.91%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Melbourne, Australia, Respiri Limited operates as an e-health software-as-a-service (SaaS) provider. The company is dedicated to the research, development, and commercialization of medical devices across Australia, and also creates, manufactures, and distributes mobile health applications. Its key offerings include wheezo, an innovative electronic tool specifically designed for identifying wheezing in children, along with the Respiri mobile application and the Respiri health portal. The organization officially became Respiri Limited in December 2015, having previously conducted business as iSonea Limited.
Key people
Peter Hildebrandt
Chief Operating Officer · since 2020
George Vlachodimitropoulos
Chief Technology Officer · since 2021
Marjan Mikel
Chief Executive Officer, Managing Director, Executive Director · since 2019
Nicholas Smedley
Executive Chairman of the Board · since 2019
Theo Antonopoulos
Chief Commercial Officer · since 2021
Samaneh Shirazi
Chief Research Officer · since 2019
Shelby Coleman
Joint Company Secretary · since 2026
Charly Duffy
Joint Company Secretary · since 2026
Justin Mouchacca
Joint Company Secretary · since 2024
Nova Taylor
Joint Company Secretary · since 2024
Jonathan Adams
Non-Executive Director · since 2025
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||